Welcome to our dedicated page for Core Scientific, Inc./tx SEC filings (Ticker: CORZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific, Inc./tx's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific, Inc./tx's regulatory disclosures and financial reporting.
Core Scientific, Inc. executive Todd M. Duchene reported a tax-related share disposition linked to equity compensation. On this Form 4, 16,741 shares of common stock were withheld at $19.08 per share to satisfy withholding tax obligations when restricted stock units vested. After this non-market, tax-withholding disposition, Duchene directly holds 2,010,348 shares of common stock.
Core Scientific CEO Adam Taylor reported a routine tax-related share disposition. On the vesting of restricted stock units, 87,355 shares of Common Stock were withheld at $19.08 per share to cover withholding tax obligations.
After this non-market transaction, Taylor directly holds 4,470,033 shares of Core Scientific common stock. Because the shares were withheld for taxes rather than sold on the open market, this filing reflects compensation and tax mechanics more than a change in investment view.
Two Seas Capital and affiliates filed an amended Schedule 13D reporting a 5.7% beneficial stake in Core Scientific, Inc. common stock. They collectively report beneficial ownership of 17,918,778 shares, including 313,646 shares issuable upon exercise of warrants and options to purchase 3,534,000 shares.
The position is held across a Strategic Fund, a Global Fund and separate Accounts, with voting and investment power delegated to Two Seas Capital under Investment Management Agreements. The filing also details a range of options positions with exercise prices between $10 and $27 and expirations on various dates in 2026, reflecting both purchased and written options tied to Core Scientific shares.
Core Scientific, Inc. officer Todd M. Duchene reported open-market sales of 10,000 shares of Common Stock on April 13, 2026, in two transactions pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. The shares were sold at weighted average prices within ranges of $17.94–$18.90 and $18.97–$19.04 per share. Following these sales, Duchene directly holds 2,027,089 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $16.4865 per share. After this sale, he directly holds 2,037,089 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and the shares were sold in multiple transactions at prices ranging from $16.285 to $16.78.
Core Scientific, Inc. Chief Executive Officer Adam Taylor reported equity compensation activity involving performance-based restricted stock units (PSUs) and related tax withholding. On March 31, 2026, he acquired 741,545 shares of Common Stock at $0.00 per share upon vesting and settlement of previously granted PSUs tied to specified performance criteria.
On the same date, 315,307 shares of Common Stock were withheld at $14.96 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, a non–open-market, tax-related disposition. After these transactions, Taylor directly held 4,557,388 shares of Common Stock, reflecting routine compensation and tax-settlement mechanics rather than open-market buying or selling.
Core Scientific, Inc. officer Todd M. Duchene reported a mix of equity compensation and share dispositions. On March 31, he received 216,734 shares of common stock through the settlement of performance-based restricted stock units, while 97,652 shares were withheld to cover tax obligations upon vesting.
On April 1, Duchene sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $15.2523 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 2,047,089 shares of Core Scientific common stock.
CORZ filing a Form 144 notice for the proposed sale of 140,000 shares of Common Stock, reported on 04/01/2026. The filing lists two underlying lots—59,388 shares from a merger/acquisition and 80,612 shares from Restricted Stock Units—that together equal the 140,000 shares.
The filing shows an aggregate amount of $2,094,400.00 and a reported shares outstanding figure of 315,332,655 as of 04/01/2026. The broker-dealer listed is Morgan Stanley Smith Barney LLC (Nasdaq). The notice documents an intended sale by an issuer-related source.
Core Scientific, Inc. outlines its 2025 shift toward high‑density colocation and AI/HPC infrastructure and seeks stockholder votes at its May 12, 2026 virtual annual meeting. The company expanded its CoreWeave agreement by 70 MW to about 590 MW of contracted capacity across five sites, with projected revenue of more than $10 billion over 12 years.
Across four locations, it advanced over 1 million square feet of data center shell, installed nearly $2 billion of infrastructure and supported more than 5 million labor hours, part of more than $5 billion of infrastructure investment largely expected to be funded by the customer. About 350 MW had been energized, with over 180 MW online and billing.
The proxy statement details three proposals: electing five directors, an advisory say‑on‑pay vote on named executive officer compensation, and ratification of KPMG as auditor. It also describes board independence, committee structure, a new cooperation agreement with Two Seas Capital on adding independent directors, and a revised executive pay program that increases performance‑based equity and links PSU vesting partly to relative total shareholder return.
Core Scientific Inc — The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares beneficially owned of Common Stock as of 03/13/2026. The filing explains an internal realignment on January 12, 2026 that disaggregated certain Vanguard subsidiaries' holdings from The Vanguard Group, Inc.
The reporting person certifies sole and shared voting and dispositive powers of 0 and states ownership is below 5%. The amendment is signed by Ashley Grim on 03/26/2026.